FAQs about Friedreich's ataxia treatment

Category: Treatment

Skyclarys (omaveloxolone) is the first therapy ever to be approved by the U.S. Food and Drug Administration (FDA) to treat Friedreich’s ataxia. Although Skyclarys is not a cure for the genetic disorder, the once-daily oral therapy has been proven to slow the progression of the disease in clinical trials.

Category: Treatment

There is no cure for Friedreich’s ataxia; however, there are therapies available that can slow the disease’s progression and ease symptoms.

Category: Treatment

Although there is no cure for Friedreich’s ataxia, a range of therapies are available that can help to ease symptoms, slow disease progression, and maintain to a certain extent a person’s functionality. In terms of medication, Skyclarys (omaveloxolone) is the only specific Friedreich’s ataxia therapy approved in the U.S.

Category: Treatment

Insurance policy coverage varies depending on the specific insurer and plan. It’s recommended that people with Friedreich’s ataxia consult with their specific insurance provider to understand what forms of coverage are available for them. In the case of Skyclarys (omaveloxolone), the first and currently only therapy approved for Friedreich’s ataxia in the U.S., the treatment’s developer, Reata Pharmaceuticals, offers support for those prescribed one of their medicines, regardless of insurance status.

Category: Treatment

Lifestyle changes cannot eliminate Friedreich’s ataxia (FA) symptoms or prevent disease progression, but some alterations in day-to-day living may be helpful; for example, regular physical exercise can help patients maintain their motor function and ease fatigue. Dietary modifications may be helpful for patients who have difficulty chewing or swallowing, and also are important for managing disease complications like diabetes. Many people with FA also benefit from the use of adaptive equipment or changes to their environment that can make daily life with the disease easier to navigate.